Last reviewed · How we verify
NCT05414786
A Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644)
Status unknown
Phase 1
Last updated 10 March 2023
What this trial tests
Phase 1 trial testing eOD-GT8 60mer mRNA Vaccine (100µg) in HIV-1-infection in 18 participants. Status unknown.
Timeline
25 May 2022
Primary endpoint
30 June 2023
30 June 2023
30 June 2023
Quick facts
| Lead sponsor | International AIDS Vaccine Initiative |
|---|---|
| Phase | Phase 1 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 18 |
| Start date | 25 May 2022 |
| Primary completion | 30 June 2023 |
| Estimated completion | 30 June 2023 |
| Sites | 2 locations across South Africa, Rwanda |
Drugs / interventions tested
- eOD-GT8 60mer mRNA Vaccine (100µg) — full drug profile →
Conditions studied
- HIV-1-infection — all drugs for HIV-1-infection →
Sponsor
International AIDS Vaccine Initiative — full company profile →
Who can join
Adults 18 to 50, any sex, with HIV-1-infection. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A Phase 1 Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644) in HIV-1 Uninfected Adults in Good General Health.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
A Comprehensive Review of mRNA Vaccines.
Gote V, Bolla PK, Kommineni N, Butreddy A, et al · · 2023 · cited 263× · PMID 36769023 · DOI 10.3390/ijms24032700 -
Vaccination induces HIV broadly neutralizing antibody precursors in humans.
Leggat DJ, Cohen KW, Willis JR, Fulp WJ, et al · · 2022 · cited 240× · PMID 36454825 · DOI 10.1126/science.add6502 -
mRNA-based vaccines and therapeutics: an in-depth survey of current and upcoming clinical applications.
Wang YS, Kumari M, Chen GH, Hong MH, et al · · 2023 · cited 93× · PMID 37805495 · DOI 10.1186/s12929-023-00977-5 -
Progress and prospects of mRNA-based drugs in pre-clinical and clinical applications.
Shi Y, Shi M, Wang Y, You J. · · 2024 · cited 67× · PMID 39543114 · DOI 10.1038/s41392-024-02002-z -
Nanoparticle technology for mRNA: Delivery strategy, clinical application and developmental landscape.
Li X, Qi J, Wang J, Hu W, et al · · 2024 · cited 47× · PMID 38169577 · DOI 10.7150/thno.84291 -
Germline-targeting HIV-1 Env vaccination induces VRC01-class antibodies with rare insertions.
Caniels TG, Medina-Ramírez M, Zhang J, Sarkar A, et al · · 2023 · cited 47× · PMID 37044090 · DOI 10.1016/j.xcrm.2023.101003 -
Prophylactic HIV-1 vaccine trials: past, present, and future.
Nkolola JP, Barouch DH. · · 2024 · cited 42× · PMID 38141639 · DOI 10.1016/s2352-3018(23)00264-3 -
Vaccination with mRNA-encoded nanoparticles drives early maturation of HIV bnAb precursors in humans.
Willis JR, Prabhakaran M, Muthui M, Naidoo A, et al · · 2025 · cited 40× · PMID 40373112 · DOI 10.1126/science.adr8382
Verify or expand the search:
- PubMed search for NCT05414786
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for HIV-1-infection
Currently open trials in the same condition.
- NCT07293559 — Understanding Practices of Lactation and Infant Feeding Together With Women With HIV in the United States · recruiting
- NCT06919016 — A Study to Evaluate the Safety and Immunogenicity of the V3-region Directed Immunogens DV700P-RNA Followed by DV701B1.1- · Phase 1 · active not recruiting
- NCT06554717 — Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV · Phase 2 · recruiting
- NCT06774872 — Doravirine/Lamivudine (DOR/3TC) as a Maintenance ART in Comparison With Dolutegravir/Lamivudine (DTG/3TC) in PLWH Succes · Phase 2 · recruiting
- NCT06890988 — Ending the Epidemic Interventions in the Dental Setting - UH3 · NA · recruiting
Other International AIDS Vaccine Initiative trials
Trials by the same sponsor.
- NCT06694753 — Safety and Immunogenicity Study of Three mRNAs Encoding HIV Immunogens in Adult Participants Without HIV and in Overall · Phase 1 · recruiting
- NCT06617091 — A Trial of a Gorilla Adenovirus Vectored Networked Epitopes Vaccine, Administered to Healthy Adults Living Without and W · Phase 1 · recruiting
- NCT06272812 — A Study to Evaluate the Efficacy, Safety and Immunogenicity of MTBVAC in Adolescents and Adults Living in a TB Endemic R · Phase 2 · recruiting
- NCT06449196 — Mosaic HIV-1 Envelope Trimer Immunogens Administered to People Living with HIV (PLWH) in Africa · EARLY_PHASE1 · withdrawn
- NCT05724472 — Evaluation of Safety and Immunogenicity of rVSVΔG-SEBOV-GP Vaccine in Adults With Good General Health · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT05414786 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by International AIDS Vaccine Initiative
- Last refreshed: 10 March 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05414786.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing